Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a)

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 10, 1997, Pages 3367-3372

  Von Eckardstein, Arnold ^a   Kliesch, Sabine ^a   Nieschlag, Eberhard ^a   Chirazi, Ali ^a   Assmann, Gerd ^a   Behre, Hermann M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; TESTOSTERONE;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY RISK; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM;

ADULT; ESTRADIOL; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; MALE; TESTOSTERONE;

EID: 0030952581     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.10.3367     Document Type: Article

References (50)

1. Barrett-Connor E, Bush TL. 1991 Estrogen and coronary heart disease in women. JAMA. 265:1861-1867.
2. Phillips GB, Yano K, Stemmermann GN. 1988 Serum sex hormones and myocardial infarction in the Honolulu Heart Program: pitfalls in prospective studies on sex hormones. J Clin Epidemiol. 41:1151-1156.
3. Mendoza SG, Osuna A, Zerpa A, Gartside PS, Glueck CJ. 1981 Hypertriglyceridemia and hypoalphalipoproteinemia in azoospermic and oligospermic young men: relationships of endogenous testosterone to triglyceride and high density lipoprotein metabolism. Metabolism. 30:481-486.
4. Hromadova M, Hacik T, Malatinsky E, Sklovsky A, Cervenakov I. 1989 Some measures of lipid metabolism in young sterile men before and after testosterone treatment. Endocr Exp. 23:205-211.
5. Sorva R, Kuusi T, Taskinene MR, Perheentupa J, Nikkila EA. 1988 Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal men. Atherosclerosis. 69:191-197.
6. Kirkland RT, Keenan BS, Probstfield JL, et al. 1987 Decrease in plasma high density lipoprotein cholesterol levels at puberty in boys with delayed adolescence. Correlation with plasma testosterone levels. JAMA. 257:502-507.
7. Zgliczynski S, Ossowski M, Slowinska-Szrednicka J, et al. 1996 Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121:35-43.
8. Ozata M, Yildrimkaya M, Bulur M, et al. 1996 Effects of gonadotropin and testosterone treatment on lipoprotein(a), high density lipoprotein particles and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab. 81:3372-3378.
9. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. 1996 Testosterone-induced suppression of lipoprotein(a) in normal men: relation to baal lipoprotein(a) level. Atherosclerosis. 122:89-95.
10. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL. 1996 Testosterone decreases lipoprotein(a) in men. Am J Cardiol. 77:1244-1247.
11. Friedel DKE, Hannan CJ, Jones RE, Kettler TM, Plymate SR. 1990 High density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 39:69-77.
12. Meriggiola MC, Bremner WJ, Paulsen CA. 1995 Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int J Androl. 18:237-242.
13. Wu FCW, Farley TMM, Peregoudov A, Waites GMH, WHO Task Force on Methods for the Regulation of Male Fertility. 1996 Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril. 65:626-636.
14. Thompson PD, Cullinane EM, Sady SP, Chenevery C, Saritelli AL, Sady MA. 1989 Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 261:1165-1168.
15. Glazer G. 1991 Atherogenic effects of anabolic steroids on serum lipid levels Steroids. 151:1925-1933.
16. Behre HM, Böckers A, Schlingheider A, Nieschlag E. 1994 Sustained suppression of serum LH, FSH, and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist Cetrorelix over 8 days in normal men. Clin Endocrinol (Oxf). 40:241-248.
17. Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ. 1992 Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Ann Intern Med. 116:967-973.
18. Goldberg RB, Rabin D, Alexander AN, Coelle GC, Getz GS. 1985 Suppression of plasma testosterone leads to increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B. J Clin Endocrinol Metab 60:203-207.
19. Behre HM, Klein B, Steinmeyer E, McGregor GP, Voigt, K, Nieschlag E. 1992 Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab. 75:393-398.
20. Behre HM, Kliesch S, Pühse G, Reissmann T, Nieschlag E. 1997 High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle stimulating hormone, and testosterone in normal men. J Clin Endocrinol Metab. 82:1403-1408.
21. Jonas A. 1991 Lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. Biochim Biophys Acta. 1084:205-225.
22. Tall AR. 1993 Plasma cholesteryl ester transfer protein. J Lipid Res. 34:1255-1274.
23. Frazer KA, Narla G, Zhang JL, Rubin EM. 1995 The apolipoprotein(a) gene is regulated by sex hormones, and acute phase inducers in YAC transgenic mice. Nat Genet. 9:424-431.
24. Friedewald WT, Levy RI, Fredrickson DS. 1972 Estimation of the concentration of low density lipoprotein in plasma without use of a preparative ultracentrifuge. Clin Chem. 18:449-456.
25. Rader DJ, Castro G, Zech LA, Fruchart JC, Brewer Jr HB. 1991 In vivo metabolism of apolipoprotein AI on high density lipoprotein particles LpA-I and LpA-I: A-II. J. Lipid Res. 32:1849-1859.
26. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. 1990 Lipoprotein(a) is an independent risk factor for myocarclial infarction at a young age. Clin Chem. 38:20-25.
27. von Eckardsfein A, Funke H, Chirazi A, et al. 1994 Sex-specific effects of the glutamine/histidine polymorphism in apolipoprotein A-IV on high density lipoprotein metabolism. Arterioscler Thromb. 14:1114-1120.
28. Nie NH. 1983 SPSSX user's guide. New York: McGraw-Hill.
29. Fruchart JC, Ailhaud G, Bard JM. 1993 Heterogeneity of high density lipoprotein particles. Circulation. 87(Suppl 3):22-27.
30. von Eckardstein A, Huang Y, Assmann G. 1994 Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol. 5:404-416.
31. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. 1994 Metabolic and behavioural effects of high dose exogenous testosterone in healthy men. J Clin Endocrinol Metab. 79:561-567.
32. Glueck CJ, Gartside P, Fallat RW, Mendoza S. 1976 Effect of sex hormones on protamine inactivated and resistant postheparin plasma lipase. Metabolism. 25:625.
33. Zmuda JM, Fahrenbachm MC, Younkin BT. 1993 The effect of testosterone aromatization on high density lipoprotein cholesterol levels and post-heparin lipolytic activity. Metabolism. 39:69-77.
34. Henriksson P, Angelin B, Berglund L. 1992 Hormonal regulation of serum Lp(a) levels. J Clin Invest. 89:1166-1171.
35. Berglund L, Carlström K, Stege R, et al. 1996 Hormonal regulation of serum lipoprotein(a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab. 81:2633-2637.
36. Arrer E, Jungwirth A, Mack D, Frick J, Patsch W. 1996 Treatment of prostate cancer with gonadotropin releasing hormone analogue: effect on lipoprotein(a). J Clin Endocrinol Metab. 81:2508-2511.
37. Sacks FM, Walsh BW. 1994 Sex hormones and lipoprotein metabolism. Curr Opin Lipidol. 5:236-240.
38. Olivecrona H, Johannson AG, Lindh E, Ljungall S, Berglund L, Angelin B. 1995 Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin like growth factor-1. Arterioscler Thromb Vasc Biol. 15:847-849.
39. Johannsson G, Oscarsson J, Rosen T, et al. 1995 Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone deficient adults: influence of gender and apo(a) and apoE phenotypes. Arterioscler Thromb Vasc Biol. 15:2142-2150.
40. Tonstad S, Sundt E, Ose L, et al. 1996 The effect of growth hormone on low density lipoprotein choesterol and lipoprotein(a) levels in familial hypercholesterolemia. Metabolism. 45.1415-1421.
41. Kung AWC, Pang RWC, Lauder I, Lam KSL, Janus ED. 1995 Changes in serum lipoprotein(a), and lipids during treatment of hyperthyroidism. Clin Chem. 41:226-231.
42. Engler H, Riesen F. 1993 Effect of thyroid function on concentration of lipoprotein(a). Clin Chem. 39:2466-2469.
43. Spandrio S, Seiman I, Scalvini T, et al. 1993 Lipoprotein(a) levels in hypothyroid and hyperthyroid patients before and after treatment. Horm Metab Res. 25:586-589.
44. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. 1992 Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 90:52-60.
45. Gordon D, Rifkind BM. 1989 Current concepts: high density lipoproteins-the clinical implications of recent studies. N Engl J Med. 321:1311-1315.
46. Assmann G, Schulte H, von Eckardstein A. 1996 Hypertriglyceridemia and elevated levels of lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 77:1179-1184.
47. Maher VMG, Brown BG. 1995 Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 6:229-235.
48. Alexandersen P, Haarbo J, Christiansen C. 1996 The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 125:1-13.
49. Nieschlag E, Nieschlag S, Behre HM. 1993 Lifespan and testosterone. Nature. 366:215.
50. Phillips GB, Pinkernell BH, Jing TY. 1994 The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 14: 701-706.